CLEVELAND, Ohio –MSC2009, the regenerative medicine and adult stem cell therapy conference, on Monday started a three-day gathering that features a largely academic audience from as far away as Brazil, Iran and Russia discussing innovations and research in the field.
Vodpod videos no longer available.
Pluristem Therapeutics is a publicly traded company that uses adult stem cells and is developing its first treatment, which would address peripheral artery disease. In addition, the company thinks it can development product to help other afflictions including Crohn’s disease, multiple sclerosis and ischemic stroke.
Its peripheral artery disease treatment, PLX-PAD, is in the midst of Phase I clinical trials in the United States and Europe, and the company planned to present details of that study at the conference.